帕比司他Farydak（panobinostat）

[Jimin Pharmaceutical Guide] Panobinostat Farydak is used in combination with other drugs to treat patients with multiple myeloma.

After failing at least two treatment options, Panobinostat Farydak can be used in combination with Velcade (bortezomib) and dexamethasone, providing another treatment option for patients with multiple myeloma.

This product is divided into three specifications: 10mg/15mg/20mg, 6 tablets per box. The method of use should be followed by the physician, and different dosing should be performed depending on the stage of the patient’s treatment.

Panobinostat Farydak is a targeted drug, a broad-spectrum protein deacetylase inhibitor, which produces a severe stress response to cancer cells by blocking histone deacetylase until cancer cells die, while normal cells are not affected. Panobinostat Farydak was developed by Takeda Pharmaceuticals and was approved in February 2015 for use in combination with other drugs to treat multiple myeloma.